Dystonia in children and adolescents: A systematic review and a new diagnostic algorithm

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 7, 2015, Pages 774-781

  Van Egmond, Martje E ^a   Kuiper, Anouk ^a   Eggink, Hendriekje ^a   Sinke, Richard J ^a   Brouwer, Oebele F ^a   Verschuuren Bemelmans, Corien C ^a   Sival, Deborah A ^a   Tijssen, Marina A J ^a   De Koning, Tom J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CARBIDOPA PLUS LEVODOPA; GLUCOSE TRANSPORTER 1; LEVODOPA; MIGLUSTAT;

ACIDURIA; ADOLESCENCE; ADOLESCENT; ANTI N METHYL DEXTRO ASPARTIC ACID RECEPTOR ENCEPHALITIS; ARTICLE; AUTOIMMUNE BASAL GANGLIA ENCEPHALITIS; AUTOIMMUNE DISEASE; CEREBRAL PALSY; CEREBROVASCULAR ACCIDENT; CHILD; CHILDHOOD; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOPA RESPONSIVE DYSTONIA; DRUG DOSE INCREASE; DRUG EXPOSURE; DYSTONIA; EARLY DIAGNOSIS; ENCEPHALITIS; GENETIC ANALYSIS; HUMAN; INBORN ERROR OF METABOLISM; LABORATORY TEST; LYSOSOME STORAGE DISEASE; MYCOPLASMA; NEXT GENERATION SEQUENCING; NIEMANN PICK DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; ORGANIC ACIDURIA; OUTCOME ASSESSMENT; PHENOMENOLOGY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RECOMMENDED DRUG DOSE; SYSTEMATIC REVIEW; TOXOPLASMOSIS; TREATMENT DURATION; TUBERCULOSIS; VIRUS INFECTION; WILSON DISEASE; ALGORITHM; CLASSIFICATION; DECISION SUPPORT SYSTEM; DIFFERENTIAL DIAGNOSIS; GENETIC SCREENING; GENETICS;

ADOLESCENT; ALGORITHMS; CHILD; DECISION SUPPORT TECHNIQUES; DIAGNOSIS, DIFFERENTIAL; DYSTONIA; GENETIC TESTING; HUMANS;

EID: 84939238828     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-309106     Document Type: Article

References (42)

1. Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013; 28: 863-73.
2. Garcia-Cazorla A, Wolf NI, Serrano M, et al. Inborn errors of metabolism and motor disturbances in children. J Inherit Metab Dis 2009; 32: 618-29.
3. Mink JW Special concerns in defining, studying, and treating dystonia in children. Mov Disord 2013; 28: 921-5.
4. de Ligt J, Willemsen MH, van Bon BW, et al. Diagnostic exome sequencing in persons with severe intellectual disability. N Engl J Med 2012; 367: 1921-9.
5. Neveling K, Feenstra I, Gilissen C, et al. A post-hoc comparison of the utility of sanger sequencing and exome sequencing for the diagnosis of heterogeneous diseases. Hum Mutat 2013; 34: 1721-6.
6. Sanger TD, Chen D, Fehlings DL, et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord 2010; 25: 1538-49.
7. Singer HS, Jankovic J, Mink JW, et al. Movement disorders in childhood. Philadelphia: Saunders Elsevier, 2010.
8. Donaldson IM, Marsden CD, Schneider SA, et al. Marsden's book of movement disorders. Oxford: Oxford University Press, 2012.
9. Defazio G, Hallett M, Hyder A, et al. Development and validation of a clinical guideline for diagnosing blepharospasm. Neurology 2013; 80: 236-40.
10. Lin JP, Lumsden DE, Gimeno H, et al. The impact and prognosis for dystonia in childhood including dystonic cerebral palsy: a clinical and demographic tertiary cohort study. J Neurol Neurosurg Psychiatry 2014; 85: 1239-44.
11. Rosenbaum P, Paneth N, Leviton A, et al. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl 2007; 109: 8-14.
12. Himmelmann K, McManus V, Hagberg G, et al.; SCPE collaboration. Dyskinetic cerebral palsy in Europe: trends in prevalence and severity. Arch Dis Child 2009; 94: 921-6.
13. MacLennan A. A template for defining a causal relation between acute intrapartum events and cerebral palsy: international consensus statement. BMJ 1999; 319: 1054-9.
14. Bax M, Tydeman C, Flodmark O. Clinical and MRI correlates of cerebral palsy: the European Cerebral Palsy Study. JAMA 2006; 296: 1602-8.
15. Moreno-De-Luca A, Ledbetter DH, Martin CL. Genetic insights into the causes and classification of cerebral palsies. Lancet Neurol 2012; 11: 283-92.
16. Dale RC, Brilot F. Autoimmune basal ganglia disorders. J Child Neurol 2012; 27: 1470-81.
17. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10: 63-74.
18. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12: 157-65.
19. Misra UK, Kalita J. Spectrum of movement disorders in encephalitis. J Neurol 2010; 257: 2052-8.
20. van Karnebeek CD, Stockler S. Treatable inborn errors of metabolism causing intellectual disability: a systematic literature review. Mol Genet Metab 2012; 105: 368-81.
21. Saudubray JM, Sedel F, Walter JH. Clinical approach to treatable inborn metabolic diseases: an introduction. J Inherit Metab Dis 2006; 29: 261-74.
22. Deodato F, Boenzi S, Santorelli FM, et al. Methylmalonic and propionic aciduria. Am J Med Genet C Semin Med Genet 2006; 142C: 104-12.
23. Pearson TS, Akman C, Hinton VJ, et al. Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS). Curr Neurol Neurosci Rep 2013; 13: 342-53.
24. Taly AB, Meenakshi-Sundaram S, Sinha S, et al. Wilson disease: description of 282 patients evaluated over 3 decades. Medicine (Baltimore) 2007; 86: 112-21.
25. Stamelou M, Tuschl K, Chong WK, et al. Dystonia with brain manganese accumulation resulting from SLC30A10 mutations: a new treatable disorder. Mov Disord 2012; 27: 1317-22.
26. Patterson MC, Mengel E, Wijburg FA, et al. Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet J Rare Dis 2013; 8: 12-22.
27. Lyseng-Williamson KA. Miglustat: a review of its use in Niemann-Pick disease type C. Drugs 2014; 74: 61-74.
28. Jankovic J. Treatment of dystonia. Lancet Neurol 2006; 5: 864-72.
29. Tadic V, Kasten M, Bruggemann N, et al. Dopa-responsive dystonia revisited: diagnostic delay, residual signs, and nonmotor signs. Arch Neurol 2012; 69: 1558-62.
30. Friedman J, Roze E, Abdenur JE, et al. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol 2012; 71: 520-30.
31. Saunders-Pullman R, Raymond D, Stoessl AJ, et al. Variant ataxia-telangiectasia presenting as primary-appearing dystonia in Canadian Mennonites. Neurology 2012; 78: 649-57.
32. Baschieri F, Batla A, Erro R, et al. Paroxysmal exercise-induced dystonia due to GLUT1 mutation can be responsive to levodopa: a case report. J Neurol 2014; 261: 615-16.
33. Keogh MJ, Daud D, Chinnery PF. Exome sequencing: how to understand it. Pract Neurol 2013; 13: 399-407.
34. Zech M, Gross N, Jochim A, et al. Rare sequence variants in ANO3 and GNAL in a primary torsion dystonia series and controls. Mov Disord 2014; 29: 143-7.
35. Assmann B, Surtees R, Hoffmann GF. Approach to the diagnosis of neurotransmitter diseases exemplified by the differential diagnosis of childhood-onset dystonia. Ann Neurol 2003; 54(Suppl 6): S18-24.
36. Gouider-Khouja N, Kraoua I, Benrhouma H, et al. Movement disorders in neuro-metabolic diseases. Eur J Paediatr Neurol 2010; 14: 304-7.
37. Haliloglu G, Vezir E, Baydar L, et al. When do we need to perform a diagnostic lumbar puncture for neurometabolic diseases? Positive yield and retrospective analysis from a tertiary center. Turk J Pediatr 2012; 54: 52-8.
38. Molero-Luis M, Serrano M, Ormazábal A, et al. Homovanillic acid in cerebrospinal fluid of 1388 children with neurological disorders. Dev Med Child Neurol 2013; 55: 559-66.
39. Roubertie A, Mariani LL, Fernandez-Alvarez E, et al. Treatment for dystonia in childhood. Eur J Neurol 2012; 19: 1292-99.
40. Thenganatt MA, Jankovic J. Treatment of dystonia. Neurotherapeutics 2014; 11: 139-52.
41. Hennekam RC, Biesecker LG. Next-generation sequencing demands next-generation phenotyping. Hum Mutat 2012; 33: 884-6.
42. Dale RC, Grattan-Smith P, Nicholson M, et al. Microdeletions detected using chromosome microarray in children with suspected genetic movement disorders: a single-centre study. Dev Med Child Neurol 2012; 54: 618-23.